The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma …

All solid tumours require a vascular supply in order to progress. Although the ability to
induce angiogenesis (new blood vessel growth) has long been regarded as essential to this …

Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …

The diagnosis and management of renal cell carcinoma have changed remarkably rapidly.
Although the incidence of renal cell carcinoma has been increasing, survival has improved …

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and …

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …